2019
TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer
Lee G, Rosenfeld J, Kim W, Kwon Y, Palapattu G, Mehra R, Kim W, Kim I. TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer. PLOS ONE 2019, 14: e0213488. PMID: 31536510, PMCID: PMC6752758, DOI: 10.1371/journal.pone.0213488.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzamidesBeta CateninCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmHumansMaleMiceMice, KnockoutNeuroendocrine CellsNitrilesPhenylthiohydantoinProstatic NeoplasmsProtein BindingProtein TransportTranscription Factor 7-Like 2 ProteinXenograft Model Antitumor AssaysConceptsCastration-resistant prostate cancerEnzalutamide resistanceTranscription factor 4Neuroendocrine differentiationProstate cancerSecond-generation androgen receptor antagonistHuman prostate cancer cell linesLNCaP human prostate cancer cell lineResistant prostate cancerProstate cancer cell linesStandard of careAndrogen receptor antagonistMouse xenograft modelExpression levelsCell linesTCF4 overexpressionCancer cell linesMedian timeClinical benefitReceptor antagonistNeuroendocrine markersMetastatic CaPTreatment resistanceXenograft modelParental cell lineDihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL
Lee G, Kim J, Kwon S, Stein M, Hong J, Nagaya N, Billakanti S, Kim M, Kim W, Kim I. Dihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer Cells via TRAIL. Endocrinology 2019, 160: 2049-2060. PMID: 31184711, PMCID: PMC6691685, DOI: 10.1210/en.2019-00367.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyCell linesHuman peripheral blood monocytesMetastatic prostate cancerPotential treatment optionPeripheral blood monocytesCytotoxicity of macrophagesHuman monocyte cell lineProstate cancer cellsCaP cell linesMonocyte cell lineVivo mouse studiesCytotoxic activityMurine macrophage cell lineApoptosis-inducing ligandConcentration-dependent mannerDeprivation therapyClodronate liposomesTreatment optionsM1 polarizationCaP tumorsAndrogen receptorMacrophage cell lineProstate cancerImmune response
2017
Intracrine androgen biosynthesis in renal cell carcinoma
Lee G, Han C, Kwon Y, Patel R, Modi P, Kwon S, Faiena I, Patel N, Singer E, Ahn H, Kim W, Kim I. Intracrine androgen biosynthesis in renal cell carcinoma. British Journal Of Cancer 2017, 116: 937-943. PMID: 28253524, PMCID: PMC5379152, DOI: 10.1038/bjc.2017.42.Peer-Reviewed Original ResearchMeSH KeywordsAbiraterone AcetateAndrogensAnimalsAntineoplastic AgentsApoptosisBenzamidesBlotting, WesternCarcinoma, Renal CellCell ProliferationDihydrotestosteroneFemaleHumansImmunoenzyme TechniquesKidney NeoplasmsMaleMiceMice, NudeNitrilesOrchiectomyPhenylthiohydantoinPrognosisProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantReal-Time Polymerase Chain ReactionReceptors, AndrogenReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTestosteroneTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsRenal cell carcinomaCastration-resistant prostate cancerRCC cell linesAnti-androgen therapyHuman RCC cell linesAndrogen biosynthesisAbiraterone acetateCell carcinomaAndrogen receptorTumor volumeCell linesAndrogen deprivation therapyHigher tumor stageProstate cancer patientsMouse xenograft studiesGenitourinary cancersTumor suppressionSignificant tumor suppressionRCC patientsTumor stageCancer patientsMale miceProstate cancerIntratumoral steroidogenesisXenograft studies
2015
Increased Expression of Androgen Receptor mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma
Ha Y, Lee G, Modi P, Kwon Y, Ahn H, Kim W, Kim I. Increased Expression of Androgen Receptor mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma. Journal Of Urology 2015, 194: 1441-1448. PMID: 25796113, DOI: 10.1016/j.juro.2015.03.078.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBlotting, WesternCarcinoma, Renal CellCell Line, TumorDisease ProgressionFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansKidney NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisReal-Time Polymerase Chain ReactionReceptors, AndrogenRetrospective StudiesRNA, NeoplasmTime FactorsYoung AdultConceptsRenal cell carcinomaAndrogen receptor mRNA expressionReceptor mRNA expression levelsCancer-specific survivalCell carcinomaCell carcinoma cell linesReceptor mRNA expressionHuman renal cell carcinoma cell linesRenal cell carcinoma cell linesAndrogen receptorMRNA expression levelsSpecific survivalCarcinoma cell linesMultivariate Cox regression analysisLocalized Renal Cell CarcinomaMRNA expressionT2 renal cell carcinomaCell linesPathological stage T1Androgen receptor expressionCox regression analysisKaplan-Meier estimatesReceptor-positive cell linesChain reactionPositive renal cell carcinomas
2014
Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction
Lee G, Kang D, Ha Y, Jung Y, Chung J, Min K, Kim T, Moon K, Chung J, Lee D, Kim W, Kim I. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction. British Journal Of Cancer 2014, 110: 1634-1644. PMID: 24518599, PMCID: PMC3960605, DOI: 10.1038/bjc.2014.23.Peer-Reviewed Original ResearchMeSH KeywordsAdultAndrogen AntagonistsAnilidesBone Morphogenetic Protein 6Bone NeoplasmsCell CommunicationCell Growth ProcessesCell Line, TumorHumansMaleMiddle AgedNeoplasm MetastasisNitrilesOrchiectomyProstatic Neoplasms, Castration-ResistantProto-Oncogene ProteinsReceptors, AndrogenRetrospective StudiesStromal CellsTosyl CompoundsWnt ProteinsWnt-5a ProteinConceptsCastration-resistant prostate cancerBone stromal cellsBone metastasesBone morphogenetic protein 6Castration resistanceCaP cell linesStromal cellsProstate cancerPrimary androgen deprivation therapyProstate-specific antigen progressionProstate cancer bone metastasisAndrogen-deprived mediumBone-tumor interactionAndrogen deprivation therapyFirst-line therapyCancer bone metastasisMetastatic prostate cancerAbsence of androgenAndrogen-depleted conditionsNF-κB pathwayCell linesPolymerase chain reaction arrayBMP-6 expressionAdvanced CaPDeprivation therapy
2013
Bone morphogenetic protein‐6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages
Lee G, Jung Y, Ha Y, Kim J, Kim W, Kim I. Bone morphogenetic protein‐6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages. Cancer Science 2013, 104: 1027-1032. PMID: 23710822, PMCID: PMC7657257, DOI: 10.1111/cas.12206.Peer-Reviewed Original ResearchMeSH KeywordsAndrogen Receptor AntagonistsAndrogensAnilidesAnimalsBenzamidesBenzofuransBone Morphogenetic Protein 6Cell Line, TumorDihydrotestosteroneHumansInterleukin-6Lymphocytes, Tumor-InfiltratingMacrophagesMaleMiceNitrilesPhenylthiohydantoinPromoter Regions, GeneticProstatic Neoplasms, Castration-ResistantQuinolinesReceptors, AndrogenTosyl CompoundsUp-RegulationConceptsCaP cell linesCastration resistanceInterleukin-6Castration-resistant prostate cancerContext of macrophagesHuman CaP cell linesExpression of ARRemoval of macrophagesAndrogen receptor mRNAProstate cancer progressionBMP-6Presence of dihydrotestosteroneProstate cancer cellsCell linesPresence of macrophagesPleiotropic growth factorBone morphogenetic proteinClodronate liposomesTRAMP-C1AR upregulationProstate cancerAndrogen hypersensitivityMacrophage coculturesReceptor mRNACell count
2011
EFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling
Kim Y, Yoon H, Kim S, Kim Y, Kim E, Kim I, Kim W. EFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling. Clinical Cancer Research 2011, 17: 4523-4530. PMID: 21571867, DOI: 10.1158/1078-0432.ccr-10-2817.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAzacitidineBiomarkers, TumorCell Line, TumorCpG IslandsDecitabineDNA MethylationDNA Modification MethylasesEpigenomicsExtracellular Matrix ProteinsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPromoter Regions, GeneticProstatic HyperplasiaProstatic NeoplasmsReproducibility of ResultsConceptsEpidermal growth factor-containing fibulin-like extracellular matrix protein 1DNA methylationGene Expression OmnibusExpression profilingProstate cell linesGenome-wide characterizationCell linesMethylation statusExtracellular matrix protein 1Methylation markersDNA methylation profilesBisulfite sequencing analysisFibulin-like extracellular matrix protein 1Aberrant methylation patternsAbnormal DNA methylationExpression levelsNovel methylation markersGene expression analysisGene expression profilingNovel DNA methylation markersMatrix protein 1Gene expression dataGene expression levelsMicroarray gene expression dataMethylation patternsMacrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6‐IL6 Loop
Lee G, Kwon S, Lee J, Jeon S, Jang K, Choi H, Lee H, Kim W, Lee D, Kim I. Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6‐IL6 Loop. The Prostate 2011, 71: 1525-1537. PMID: 21374653, DOI: 10.1002/pros.21369.Peer-Reviewed Original ResearchConceptsProstate cancer cellsHormone-refractory prostate cancerRefractory prostate cancerNeuroendocrine differentiationBone morphogenetic protein 6IL-6Cancer cellsProstate cancerInterleukin-6 knockout miceTRAMP-C2 cell lineHuman prostate cancer tissuesNeuroendocrine cellsCell linesParathyroid hormone-related peptideTRAMP-C2 prostate cancer cellsTRAMP-C2 cellsMacrophage-depleted miceProstate Cancer Neuroendocrine DifferentiationIL-6 expressionTHP-1 human monocytic cell lineHormone-related peptideProstate cancer tissuesHuman monocytic cell lineRAW 264.7 murine macrophage cell lineEffect of macrophages
2009
Bone morphogenetic protein‐6 induces the expression of inducible nitric oxide synthase in macrophages
Kwon S, Lee G, Lee J, Kim W, Kim I. Bone morphogenetic protein‐6 induces the expression of inducible nitric oxide synthase in macrophages. Immunology 2009, 128: e758-e765. PMID: 19740337, PMCID: PMC2753926, DOI: 10.1111/j.1365-2567.2009.03079.x.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, NeutralizingBone Morphogenetic Protein 6Cells, CulturedCycloheximideDactinomycinHumansInterleukin-1betaMacrophages, PeritonealMiceNF-kappa BNitric Oxide Synthase Type IIProtein Synthesis InhibitorsRecombinant ProteinsSignal TransductionSmad ProteinsTumor Necrosis Factor-alphaConceptsBone morphogenetic proteinBMP-6Effects of BMPBone morphogenetic protein 6New protein synthesisMorphogenetic proteinsMurine macrophage cell lineMacrophage cell lineImportant regulatorProtein synthesisProtein 6Cell typesMouse peritoneal macrophagesCell linesActinomycin DNF-kappaBSmadExpressionDose-dependent mannerSynthaseNitric oxide synthasePathwayInductionInducible nitric oxide synthasePeritoneal macrophages
2006
Expression of estrogen receptors‐α and ‐β in bladder cancer cell lines and human bladder tumor tissue
Shen S, Smith C, Hsieh J, Yu J, Kim I, Jian W, Sonpavde, Ayala G, Younes M, Lerner S. Expression of estrogen receptors‐α and ‐β in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006, 106: 2610-2616. PMID: 16700038, DOI: 10.1002/cncr.21945.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBlotting, WesternCarcinoma, Transitional CellCell Line, TumorCell ProliferationEstradiolEstrogen Receptor alphaEstrogen Receptor betaFulvestrantGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryMicroarray AnalysisNeoplasm StagingRaloxifene HydrochlorideReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTamoxifenUrinary Bladder NeoplasmsConceptsBladder cancer cell linesExpression of ERbetaCancer cell linesERbeta expressionHuman bladder cancerBladder cancer cellsBladder cancerEstrogen receptorWestern blot analysisT4 tumorsCell linesMetastatic transitional cell carcinomaMuscle-invasive bladder cancerER-alpha mRNA levelsT3/T4 tumorsHuman bladder tumor tissuesRT4 cellsBladder cancer cell growthLevels of ERalphaGrade 3 tumorsCancer cellsInvasive bladder cancerTa/T1Transitional cell carcinomaEffects of estradiol
2004
Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1
Kim I, Lee D, Lee D, Kim W, Kim M, Morton R, Lerner S, Kim S. Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1. Cancer Research 2004, 64: 7355-7360. PMID: 15492256, DOI: 10.1158/0008-5472.can-04-0154.Peer-Reviewed Original ResearchConceptsTSU-Pr1Cell line TSU-Pr1BMP-RIITumor growthBladder transitional cell carcinoma cellsHuman bladder cancer cell linesCell linesTransitional cell carcinoma cellsBladder cancer cell linesBone morphogenetic protein receptor type II (BMPR2) expressionBone morphogenetic proteinTSU-Pr1 cellsBladder TCC tissuesGrowth inhibitory effectsCancer cell linesBladder specimensType II expressionBladder TCCTumor gradeTransitional epitheliumClinical observationsTCC tissuesMalignant cellsSignificant associationBMP-RIALoss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells
Kim I, Lee D, Lee D, Ahn H, Kim M, Kim S, Morton R. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 2004, 23: 7651-7659. PMID: 15354178, DOI: 10.1038/sj.onc.1207924.Peer-Reviewed Original ResearchConceptsBone morphogenetic proteinProstate cancer cellsHuman prostate cancer cellsLoss of expressionProstate cancer patientsBMP-RIICancer patientsGleason scoreBMP receptor type IABone morphogenetic protein receptor type IICancer cellsSignificant associationHuman prostate cancer cell linesBiochemical recurrence-free rateExpression of BMPRsRecurrence-free rateProstate cancer cell linesCell linesTumor growth rateReceptor type IIParental cell lineCancer cell linesMorphogenetic proteinsClinical stagePrognostic value735: Differential Expression of Estrogen Receptor α and β in Bladder Cancer Cell Lines and Human Bladder Tumor Tissue
Shen S, Yu J, Kim I, Jian W, Matsumoto K, Kim M, Sonpavde G, Smith C, Ayala G, Younes M, Lerner S. 735: Differential Expression of Estrogen Receptor α and β in Bladder Cancer Cell Lines and Human Bladder Tumor Tissue. Journal Of Urology 2004, 171: 195. DOI: 10.1016/s0022-5347(18)37984-9.Peer-Reviewed Original Research
2002
Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
Kim I, Kim B, Seong D, Lee D, Seo J, Hong Y, Kim H, Morton R, Kim S. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Research 2002, 62: 5365-9. PMID: 12235008.Peer-Reviewed Original ResearchConceptsAndrogen-independent human prostate cancer cell linesMixed estrogen agonist/antagonistProstate cancer cell linesHuman prostate cancer cell linesEstrogen agonist/antagonistAgonists/antagonistsCancer cell linesER betaER alphaCell linesDU145 cellsSelective estrogen receptor modulatorsEffects of raloxifeneEstrogen receptor modulatorsPC3M cellsDose-dependent mannerCell deathM raloxifeneWestern blot analysisTime-dependent mannerRaloxifene treatmentReceptor modulatorsBreast cancerPan-caspase inhibitor zVADRaloxifeneRaloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells*
Kim H, Kim B, Kim I, Mamura M, Seong H, Jang J, Kim S. Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells*. Journal Of Biological Chemistry 2002, 277: 32510-32515. PMID: 12084714, DOI: 10.1074/jbc.m202852200.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid Chloromethyl KetonesAntineoplastic AgentsApoptosisBcl-Associated Death ProteinBcl-X ProteinCarrier ProteinsCaspase 3CaspasesCell DivisionCell MembraneCell NucleusCycloheximideCytochrome c GroupDNA FragmentationDose-Response Relationship, DrugEstrogen Receptor ModulatorsHumansIn Situ Nick-End LabelingMembrane PotentialsMitochondriaPhosphorylationProtein BindingProtein Synthesis InhibitorsProto-Oncogene Proteins c-bcl-2Raloxifene HydrochlorideRetroviridaeTime FactorsTumor Cells, CulturedUrinary Bladder NeoplasmsConceptsMixed estrogen agonist/antagonistTSU-Pr1 cell linesEstrogen agonist/antagonistTSU-Pr1 cellsAgonists/antagonistsCell linesSelective estrogen receptor modulatorsHuman bladder transitional cell carcinoma cell lineEffects of raloxifeneTransitional cell carcinoma cell linesProstate cancer cell linesEstrogen receptor modulatorsCell carcinoma cell linesEstrogen receptor betaHuman bladder cancerDose-dependent mannerEvidence of apoptosisCancer cell linesRaloxifene treatmentCarcinoma cell linesBladder cancerReceptor modulatorsBreast cancerHuman cancer cellsRaloxifene
1998
ABSENCE OF EXPRESSION OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, RENCA
KUNDU S, KIM I, ZELNER D, JANULIS L, GOODWIN S, ENGEL J, LEE C. ABSENCE OF EXPRESSION OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, RENCA. Journal Of Urology 1998, 160: 1883-1888. PMID: 9783979, DOI: 10.1016/s0022-5347(01)62437-6.Peer-Reviewed Original ResearchConceptsTGF-beta1 productionRenca cellsTGF-beta sensitivityRenal carcinoma cell linesCarcinoma cell linesInhibitory effectEndogenous TGF-beta1 productionWild-type Renca cellsCell linesTGF-beta receptor expressionTbetaR-II mRNAAggressive growth patternGrowth factor beta type II receptorTGF-beta1 mRNATGF-beta insensitivityPlasminogen activator inhibitorTbetaR-I mRNAType II receptorAbsence of expressionReceptor expressionTbetaR-IIII receptorsActivator inhibitorAggressive growthThymidine incorporationABSENCE OF EXPRESSION OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, RENCA
KUNDU S, KIM I, ZELNER D, JANULIS L, GOODWIN S, ENGEL J, LEE C. ABSENCE OF EXPRESSION OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, RENCA. Journal Of Urology 1998, 160: 1883-1888.. DOI: 10.1097/00005392-199811000-00077.Peer-Reviewed Original ResearchT beta RRenca cellsTGF-beta sensitivityRenal carcinoma cell linesCarcinoma cell linesBeta RInhibitory effectWild-type Renca cellsCell linesTGF-beta receptor expressionAggressive growth patternGrowth factor beta type II receptorTGF-beta insensitivityPlasminogen activator inhibitorType II receptorAbsence of expressionReceptor expressionII receptorsActivator inhibitorAggressive growthTumor cellsThymidine incorporationRT-PCRCancer cellsReceptorsThe Conventional Transforming Growth Factor-β (TGF-β) Receptor Type I Is Not Required for TGF-β1 Signaling in a Human Prostate Cancer Cell Line, LNCaP
Kim I, Zelner D, Lee C. The Conventional Transforming Growth Factor-β (TGF-β) Receptor Type I Is Not Required for TGF-β1 Signaling in a Human Prostate Cancer Cell Line, LNCaP. Experimental Cell Research 1998, 241: 151-160. PMID: 9633523, DOI: 10.1006/excr.1998.4034.Peer-Reviewed Original ResearchMeSH KeywordsActivin Receptors, Type IDihydrotestosteroneGene ExpressionHumansMaleProstatic NeoplasmsProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaRNA, MessengerSensitivity and SpecificitySignal TransductionTransforming Growth Factor betaTumor Cells, CulturedConceptsHuman prostate cancer cell linesCompetitive quantitative RT-PCRProstate cancer cell linesType II receptorLNCaP cellsII receptorsWestern blot analysisQuantitative RT-PCRCancer cell linesTGF-beta signalingALK-5RT-PCRALK-1Androgen-responsive human prostate cancer cell lineGrowth factor-β receptor type IType II receptor mRNAReceptor type IConcentrations of dihydrotestosteroneTGF-β1 signalingCell linesBlot analysisType INM dihydrotestosteroneReceptor mRNADihydrotestosterone
1996
Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP
Kim I, Kim J, Zelner D, Ahn H, Sensibar J, Lee C. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. Endocrinology 1996, 137: 991-999. PMID: 8603613, DOI: 10.1210/endo.137.3.8603613.Peer-Reviewed Original ResearchConceptsDoses of dihydrotestosteroneProstatic cancer cell linesLNCaP cellsCancer cell linesTGF-beta1 messenger RNART-PCRCompetitive quantitative RT-PCRTGF-beta1 proteinDose-dependent increaseGrowth arrestEnzyme-linked immunoadsorbent assayCell linesTGF-beta1 neutralizing antibodyActivation of latentDose-response curveMessenger RNALNCaP proliferationQuantitative RT-PCRWestern blot analysisNeutralizing antibodiesLinear dose-response curveHigh doseTGF-beta1Immunoadsorbent assayGrowth factorGenetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells.
Kim I, Ahn H, Zelner D, Shaw J, Sensibar J, Kim J, Kato M, Lee C. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Research 1996, 56: 44-8. PMID: 8548772.Peer-Reviewed Original ResearchConceptsProstate cancer cell linesLNCaP cellsProstate cancer cellsType I receptorT beta RCancer cell linesI geneDU145 cellsGenetic changesTGF-beta receptor type III receptorTGF-beta receptor expressionGrowth factor beta 1Beta RCancer cellsHuman prostate cancer cellsProliferation of PC3TGF-beta signalsBlot analysisReceptor type IICell linesDose-dependent mannerSouthern blot analysisType I geneType II receptor